RxDoctor Payments Data

Susan Brown

Nurse Practitioner · Gainesville, GANPI 1669502522

Payments from drug & device makers

$5,561in general payments, 2019–2025

Across 241 payments — averaging $23.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sanofi$908
  • Amgen$514
  • Regeneron Healthcare Solutions, Inc.$424
  • GSK$369
  • Takeda Pharmaceuticals U.S.A., Inc.$326
  • plus $2K from 20 others

What the payments were for

  • Food & beverage$5,43898%
  • Education$1232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,561 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$18,640
Medicare patients
72
Services billed
735

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$57,121
Breo ElliptaFluticasone/Vilanterol64$40,785
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$24,692
Spiriva RespimatTiotropium Bromide21$17,036
Advair HfaFluticasone Propion/Salmeterol29$13,487
SymbicortBudesonide/Formoterol Fumarate36$11,143
Fluticasone-VilanterolFluticasone/Vilanterol21$9,846
Arnuity ElliptaFluticasone Furoate23$7,449
Fluticasone-SalmeterolFluticasone Propion/Salmeterol39$7,411
Qvar RedihalerBeclomethasone Dipropionate24$7,007
Epinephrine27$5,281
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$5,073
Mometasone Furoate61$3,446
Wixela InhubFluticasone Propion/Salmeterol18$2,892
Azelastine Hcl83$2,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta$369$110,428179 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,099$35,83568 claims
Boehringer IngelheimSpiriva Respimat$278$17,03621 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$108$7,00724 claims
Hikma Pharmaceuticals USAEpinephrine$58$5,28127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →